Literature DB >> 15871680

Factors associated with induced chronic inflammation in mdx skeletal muscle cause posttranslational stabilization and augmentation of extrasynaptic sarcolemmal utrophin.

Ishrat Waheed1, Rénald Gilbert, Josephine Nalbantoglu, Ghiabe H Guibinga, Basil J Petrof, George Karpati.   

Abstract

Chronic inflammation in tibialis anterior muscles of mdx mice was produced by a single injection of a recombinant adenovirus vector (AV) expressing an immunogenic beta-galactosidase (beta-gal). In regions of intense beta-gal staining, mononuclear infiltrates abounded, and muscle fibers showed strong extrasynaptic utrophin immunostaining, restoration of dystrophin-associated protein complex, and a marked reduction of the prevalence of centronucleation. Immunoblot analysis confirmed an increase of endogenous utrophin without an increase of the mRNA of the major muscle isoform utrA. Significantly better maximal tetanic force values were demonstrated in the inflammatory versus control mdx muscles. The resistance to lengthening contraction- induced damage was also significantly increased in the former. In muscles of mice lacking TNF-alpha gene, AV vector did not induce inflammation and extrajunctional utrophin increase did not occur. In the inflammatory mdx muscles, proteolytic activity of calcium-activated calpain was reduced, and in mdx myotubes in vitro, incubation with NO donors also reduced calpain-mediated utrophin proteolysis. Since utrophin was shown to be a natural substrate of calpain and known inhibitors of calpain in cultured mdx myotubes increased utrophin levels, the above results were consistent with the following conclusions: (1) extrasynaptic utrophin increase is mainly responsible for the antidystrophic effect; (2) extrasynaptic utrophin increase is a result of posttranscriptional mechanism(s) related to proinflammatory factors; and (3) reduction of endogenous muscle calpain activity by inflammatory cytokines has an important role in the stabilization and increase of the extrasynaptic utrophin.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15871680     DOI: 10.1089/hum.2005.16.489

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  5 in total

Review 1.  Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances.

Authors:  Guy L Odom; Paul Gregorevic; Jeffrey S Chamberlain
Journal:  Biochim Biophys Acta       Date:  2006-09-26

2.  Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency.

Authors:  M Khairallah; R J Khairallah; M E Young; B G Allen; M A Gillis; G Danialou; C F Deschepper; B J Petrof; C Des Rosiers
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-12       Impact factor: 11.205

3.  BMP type I receptor inhibition reduces heterotopic [corrected] ossification.

Authors:  Paul B Yu; Donna Y Deng; Carol S Lai; Charles C Hong; Gregory D Cuny; Mary L Bouxsein; Deborah W Hong; Patrick M McManus; Takenobu Katagiri; Chetana Sachidanandan; Nobuhiro Kamiya; Tomokazu Fukuda; Yuji Mishina; Randall T Peterson; Kenneth D Bloch
Journal:  Nat Med       Date:  2008-11-30       Impact factor: 53.440

4.  MicroRNAs modulated by local mIGF-1 expression in mdx dystrophic mice.

Authors:  Laura Pelosi; Angela Coggi; Laura Forcina; Antonio Musarò
Journal:  Front Aging Neurosci       Date:  2015-05-05       Impact factor: 5.750

5.  A six‑gene support vector machine classifier contributes to the diagnosis of pediatric septic shock.

Authors:  Guoli Long; Chen Yang
Journal:  Mol Med Rep       Date:  2020-01-23       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.